EGFR and non-small cell lung carcinoma: In order to evaluate the efficacy and safety of toripalimab plus carboplatin and pemetrexed in previously EGFR-TKI-treated patients with EGFR-mutant NSCLC, we conducted this open-label, single-arm phase-II trial and enrolled 40 patients from eight medical centers in China.